Methylation markers in prostate biopsies are prognosticators for late biochemical recurrence and therapy after surgery in prostate cancer patients

Publication date: Available online 9 October 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Andrea J. Savio, Shivani Kamdar, Renu Jeyapala, Ekaterina Olkhov-Mitsel, Carmelle Cuizon, Antonio Finelli, Alexandre R. Zlotta, Ants Toi, Neil E. Fleshner, Theodorus van der Kwast, Bharati BapatAbstractAfter diagnosis of prostate cancer is confirmed by a positive biopsy, the tumor may be surgically removed via radical prostatectomy (RP). However, many prostate cancer patients experience biochemical recurrence post-surgery and/or undergo salvage radiotherapy or hormone therapy. Timely treatment is required to prevent the spread of disease in these cases, and biopsy tissue may hold potential for disease prognostication before surgery is ever performed. We previously developed a prognostic multi-gene methylation panel in RP specimens, including APC, CRIP3, HOXD3, and TGFB2. In the current study, this panel was applied to a cohort of biopsy specimens (n=86), which were assessed for DNA methylation using the qPCR-based multiplex MethyLight. The biopsy-based methylation panel is significantly associated with biochemical recurrence when combined with the current clinical parameter of prostate-specific antigen (PSA) levels at diagnosis, and is able to prognosticate the initiation of salvage radiotherapy, where it outperforms PSA, and/or hormone therapy following RP. Additionally, this methylation panel is significantly associated with late recurrence occurring within five and seven...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research